Literature DB >> 8045522

The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices.

M M Ott1, G Ott, R Kuse, P Porowski, U Gunzer, A C Feller, H K Müller-Hermelink.   

Abstract

Ten cases of classic centrocytic lymphoma as defined in the Kiel classification system were investigated for their immunophenotype, their proliferation activity and by means of molecular diagnostics. The findings were compared to those obtained from a group of nine cases of anaplastic centrocytic lymphoma. Both groups showed virtually identical immunohistochemical characteristics with positivity for CD5 and negativity for CD10 and CD23. In the group of anaplastic centrocytic lymphoma, there were considerably higher proliferation indices as documented by staining for the Ki-67 antigen, up to 80% of the tumour cells being positive. Moreover, the cases of anaplastic centrocytic lymphoma had bcl-1 gene rearrangements in eight out of nine cases compared with three out of 10 cases of classic centrocytic lymphoma. DNA analysis was not able to detect bcl-2 gene rearrangement in any case, pointing to a difference compared with lymphomas of germinal centre origin. The coincidence of anaplastic and sometimes blast-like morphology of the tumour cells, high proliferation index and a rearranged bcl-1 gene in nearly all cases of anaplastic centrocytic lymphoma support their classification as high-grade malignant variants of centrocytic lymphoma and suggest a possible role for the bcl-1 locus not only in the origin but also in the progression of centrocytic lymphomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045522     DOI: 10.1111/j.1365-2559.1994.tb00533.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

Review 1.  Molecular pathology of low grade malignant lymphomas.

Authors:  H Ratech
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

2.  Blastoid variant of mantle cell lymphoma with lactic acidosis: a case report.

Authors:  Korenori Ohtsubo; Rie Imamura; Ritsuko Seki; Koichi Ohshima; Michitoshi Hashiguchi; Kazuaki Yakushiji; Koji Yoshimoto; Hideaki Ogata; Takashi Okamura; Michio Sata
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

3.  Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas.

Authors:  N S Aguilera; K E Bijwaard; B Duncan; A E Krafft; W S Chu; S L Abbondanzo; J H Lichy; J K Taubenberger
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

4.  Potential effects of CRM1 inhibition in mantle cell lymphoma.

Authors:  Ke-Jie Zhang; Michael Wang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

5.  Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.

Authors:  L Quintanilla-Martinez; C Thieblemont; F Fend; S Kumar; M Pinyol; E Campo; E S Jaffe; M Raffeld
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

Review 6.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

7.  De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow Necrosis without Adenopathy or Organomegaly.

Authors:  Ghaleb Elyamany; Ali Matar Alzahrani; Eman Al Mussaed; Hassan Aljasem; Sultan Alotaibi; Hatem Elghezal
Journal:  Case Rep Hematol       Date:  2015-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.